重组人脑利钠肽对慢性肾脏病患者行PCI后造影剂肾病的预防价值

目的:探讨重组人脑利钠肽对慢性肾脏病(CKD)患者行冠状动脉介入(PCI)治疗后造影剂肾病(CIN)的预防作用.方法:选择我科2017年1月-2021年1月行PCI治疗的CKD患者108例,随机分为重组人脑利钠肽组(52例)和对照组(56例),重组人脑利钠肽组在行PCI前12h给予重组人脑利钠肽0.005 μg·kg-...

Prophylactic value of Lyophilized Recombinant Human Brain Natriuretic Peptide in the contrast-induced nephropathy after coronary interventional therapy in patients with chronic kidney disease

Objective: To investigate the prophylactic value of Lyophilized Recombinant Human Brain Natriuretic Peptide(Xinhuosu) in the contrast-induced nephropathy(CIN) in patients with chronic kidney disease(CKD) after coronary interventional therapy. Methods: A total of 108 patients with chronic kidney disease who underwent coronary interventional therapy in our department from January 2017 to January 2021, were randomized to the Xinhuosu group(n=52 cases) and the control group(n=56 cases). Patients in the Xinhuosu group received 0.005 ug/kg/min of Xinhuosu for 12 hours before coronary intervention, and at 12 hours after coronary intervention, meanwhile 0.9% NaCL at 1.0 ml/kg/h for 12 hours before and 12 hours after coronary intervention. The control group received hydration treatment only, and the incidence of CIN were analyzed. We recorded the changes of serum creatinine, eGFR and Cys C before coronary intervention and 24 h, 48 h, 1 week, and 1 month after coronary intervention. Results: Compared with the control group, the incidence of CIN in the Xinhuosu group was significantly lower(6.2% vs 16.4%, P<0.05). Moreover, compared with the Xinhuosu group, the levels of SCr, eGFR and Cys C in the control group were significant deterioration postoperatively from 48 h to 1 week(P<0.05). Although a gradual decrease in eGFR was observed in both groups, but in the Xinhuosu group, the decrease in eGFR was mild and recovered quickly. Conclusion: For patients with CKD, Xinhuosu combined with hydration therapy can significantly reduce the incidence of CIN.